United-Guardian Reports Third Quarter Financial Results
United-Guardian, Inc. (NASDAQ:UG) reported a net income of $717,532 ($0.16 per share) on sales of $2,336,360 for Q3 2020, a decline from $1,069,871 ($0.23 per share) on $3,317,370 in Q3 2019. Year-to-date, net income stands at $2,694,450 ($0.59 per share) with sales of $8,613,918, compared to $3,371,375 ($0.73 per share) on $9,777,086 in the same period last year. The decline is attributed to the pandemic's impact on consumer demand, particularly in personal care products, while pharmaceutical product demand increased by 9% and 15% for the quarter and year-to-date, respectively.
- 9% increase in pharmaceutical product demand for Q3 2020.
- 15% increase in pharmaceutical product demand for the first nine months of 2020.
- Net sales decreased from $3,317,370 in Q3 2019 to $2,336,360 in Q3 2020.
- Net income dropped from $1,069,871 in Q3 2019 to $717,532 in Q3 2020.
- Year-to-date sales fell from $9,777,086 in 2019 to $8,613,918 in 2020.
- Reduced demand for cosmetic ingredients, especially in China, expected to last at least until year-end.
HAUPPAUGE, N.Y., Nov. 10, 2020 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) today reported net income of
Ken Globus, President of United-Guardian, stated, “As we anticipated, sales and earnings for the third quarter were impacted by the coronavirus pandemic to a greater degree than they were in the first and second quarters, which we believe was primarily due to the overall global decrease in consumer demand for personal care products. In addition to manufacturers cutting back on production, the coronavirus also caused the temporary closing of many manufacturing facilities, all of which reduced the need for our products and resulted in many distributors holding excess inventory that has to be worked off.”
“On a positive note, demand for our pharmaceutical products increased by
United-Guardian is a manufacturer of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products.
Contact:
Ken Globus
Investor Relations
(631) 273-0900
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
STATEMENTS OF INCOME*
FOR THE
THREE AND NINE MONTHS ENDED
SEPTEMBER 30,
2020 and 2019
(UNAUDITED)
THREE MONTHS ENDED SEPTEMBER 30, | NINE MONTHS ENDED SEPTEMBER 30, | |||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||
Net Sales | $ | 2,336,360 | $ | 3,317,370 | $ | 8,613,918 | $ | 9,777,086 | ||||
Costs and expenses: | ||||||||||||
Cost of sales | 974,763 | 1,386,948 | 3,634,528 | 4,142,616 | ||||||||
Operating expenses | 493,204 | 544,176 | 1,520,114 | 1,593,232 | ||||||||
Research and development | 114,836 | 104,800 | 331,134 | 297,304 | ||||||||
Total costs and expenses | 1,582,803 | 2,035,924 | 5,485,776 | 6,033,152 | ||||||||
Income from operations | 753,557 | 1,281,446 | 3,128,142 | 3,743,934 | ||||||||
Other Income: | ||||||||||||
Investment income | 38,932 | 47,320 | 131,318 | 141,428 | ||||||||
Net gain on marketable securities | 113,248 | 25,499 | 143,832 | 369,542 | ||||||||
Total other income | 152,180 | 72,819 | 275,150 | 510,970 | ||||||||
Income before provision for income taxes | 905,737 | 1,354,265 | 3,403,292 | 4,254,904 | ||||||||
Provision for income taxes | 188,205 | 284,394 | 708,842 | 883,529 | ||||||||
Net Income | $ | 717,532 | $ | 1,069,871 | $ | 2,694,450 | $ | 3,371,375 | ||||
Earnings per common share (Basic and Diluted) | $ | 0.16 | $ | 0.23 | $ | 0.59 | $ | 0.73 | ||||
Weighted average shares – basic and diluted | 4,594,319 | 4,594,319 | 4,594,319 | 4,594,319 |
* Additional financial information can be found at the company’s web site at www.u-g.com.
FAQ
What were the earnings results for United-Guardian in Q3 2020?
How did net sales change for United-Guardian in Q3 2020 compared to last year?
What is the future outlook for United-Guardian's cosmetic ingredient demand?